Monitoring the Responsiveness of T and Antigen Presenting Cell Compartments in Breast Cancer Patients is Useful to Predict Clinical Tumor Response to Neoadjuvant Chemotherapy

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2018 Jan 17

PMID 29334915

Citations 8

Authors

David A Bernal-Estevez

Oscar Garcia

Ramiro Sanchez

Carlos A Parra-Lopez

Affiliations

Soon will be listed here.

Abstract

Background: Vaccination of mice with tumors treated with Doxorubicin promotes a T cell immunity that relies on dendritic cell (DC) activation and is responsible for tumor control in vaccinated animals. Despite Doxorubicin in combination with Cyclophosphamide (A/C) is widely used to treat breast cancer patients, the stimulating effect of A/C on T and APC compartments and its correlation with patient's clinical response remains to be proved.

Methods: In this prospective study, we designed an in vitro system to monitor various immunological readouts in PBMCs obtained from a total of 17 breast cancer patients before, and after neoadjuvant anti-tumor therapy with A/C.

Results: The results show that before treatment, T cells and DCs, exhibit a marked unresponsiveness to in vitro stimulus: whereas T cells exhibit poor TCR internalization and limited expression of CD154 in response to anti-CD3/CD28/CD2 stimulation, DCs secrete low levels of IL-12p70 and limited CD83 expression in response to pro-inflammatory cytokines. Notably, after treatment the responsiveness of T and APC compartments was recovered, and furthermore, this recovery correlated with patients' residual cancer burden stage.

Conclusions: Our results let us to argue that the model used here to monitor the T and APC compartments is suitable to survey the recovery of immune surveillance and to predict tumor response during A/C chemotherapy.

Citing Articles

Injectable supramolecular hydrogel co-loading abemaciclib/NLG919 for neoadjuvant immunotherapy of triple-negative breast cancer.

Zhu B, Cai Y, Zhou L, Zhao L, Chen J, Shan X Nat Commun. 2025; 16(1):687.

PMID: 39814714 PMC: 11735626. DOI: 10.1038/s41467-025-55904-z.

Advances in predicting breast cancer driver mutations: Tools for precision oncology (Review).

Hao W, Rajendran B, Cui T, Sun J, Zhao Y, Palaniyandi T Int J Mol Med. 2024; 55(1).

PMID: 39450552 PMC: 11537269. DOI: 10.3892/ijmm.2024.5447.

Effect of neoadjuvant chemotherapy on tumor immune infiltration in breast cancer patients: Systematic review and meta-analysis.

Llano-Leon M, Martinez-Enriquez L, Rodriguez-Bohorquez O, Velandia-Vargas E, Lalinde-Ruiz N, Villota-Alava M PLoS One. 2023; 18(4):e0277714.

PMID: 37104271 PMC: 10138237. DOI: 10.1371/journal.pone.0277714.

Neoadjuvant chemotherapy modulates exhaustion of T cells in breast cancer patients.

Rodriguez I, Bernal-Estevez D, Llano-Leon M, Bonilla C, Parra-Lopez C PLoS One. 2023; 18(2):e0280851.

PMID: 36763585 PMC: 9916600. DOI: 10.1371/journal.pone.0280851.

The application basis of immuno-checkpoint inhibitors combined with chemotherapy in cancer treatment.

Shi M, Liu H, Chen X, Tian Y, Chen Z, Wang K Front Immunol. 2023; 13:1088886.

PMID: 36703971 PMC: 9871553. DOI: 10.3389/fimmu.2022.1088886.

References

Diaz-Montero C, Salem M, Nishimura M, Garrett-Mayer E, Cole D, Montero A . Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother. 2008; 58(1):49-59. PMC: 3401888. DOI: 10.1007/s00262-008-0523-4. View

Martinuzzi E, Afonso G, Gagnerault M, Naselli G, Mittag D, Combadiere B . acDCs enhance human antigen-specific T-cell responses. Blood. 2011; 118(8):2128-37. DOI: 10.1182/blood-2010-12-326231. View

Cella M, Scheidegger D, Lane P, Lanzavecchia A, Alber G . Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med. 1996; 184(2):747-52. PMC: 2192696. DOI: 10.1084/jem.184.2.747. View

Krowka J, Cuevas B, Maron D, Steimer K, Ascher M, Sheppard H . Expression of CD69 after in vitro stimulation: a rapid method for quantitating impaired lymphocyte responses in HIV-infected individuals. J Acquir Immune Defic Syndr Hum Retrovirol. 1996; 11(1):95-104. DOI: 10.1097/00042560-199601010-00013. View

Fraser Symmans W, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V . Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007; 25(28):4414-22. DOI: 10.1200/JCO.2007.10.6823. View

Yu J, Du W, Yan F, Wang Y, Li H, Cao S . Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. J Immunol. 2013; 190(7):3783-97. DOI: 10.4049/jimmunol.1201449. View

Desmedt C, Di Leo A, de Azambuja E, Larsimont D, Haibe-Kains B, Selleslags J . Multifactorial approach to predicting resistance to anthracyclines. J Clin Oncol. 2011; 29(12):1578-86. DOI: 10.1200/JCO.2010.31.2231. View

Markowitz J, Wesolowski R, Papenfuss T, Brooks T, Carson 3rd W . Myeloid-derived suppressor cells in breast cancer. Breast Cancer Res Treat. 2013; 140(1):13-21. PMC: 3773691. DOI: 10.1007/s10549-013-2618-7. View

Vacchelli E, Galluzzi L, Rousseau V, Rigoni A, Tesniere A, Delahaye N . Loss-of-function alleles of P2RX7 and TLR4 fail to affect the response to chemotherapy in non-small cell lung cancer. Oncoimmunology. 2012; 1(3):271-278. PMC: 3382853. DOI: 10.4161/onci.18684. View

10.

Datta J, Rosemblit C, Berk E, Showalter L, Namjoshi P, Mick R . Progressive loss of anti-HER2 CD4 T-helper type 1 response in breast tumorigenesis and the potential for immune restoration. Oncoimmunology. 2015; 4(10):e1022301. PMC: 4589053. DOI: 10.1080/2162402X.2015.1022301. View

11.

Della Bella S, Gennaro M, Vaccari M, Ferraris C, Nicola S, Riva A . Altered maturation of peripheral blood dendritic cells in patients with breast cancer. Br J Cancer. 2003; 89(8):1463-72. PMC: 2394334. DOI: 10.1038/sj.bjc.6601243. View

12.

Bernal-Estevez D, Sanchez R, Tejada R, Parra-Lopez C . Chemotherapy and radiation therapy elicits tumor specific T cell responses in a breast cancer patient. BMC Cancer. 2016; 16:591. PMC: 4971722. DOI: 10.1186/s12885-016-2625-2. View

13.

Campbell K, Ovendale P, Kennedy M, Fanslow W, Reed S, Maliszewski C . CD40 ligand is required for protective cell-mediated immunity to Leishmania major. Immunity. 1996; 4(3):283-9. DOI: 10.1016/s1074-7613(00)80436-7. View

14.

Kelsall B, Stuber E, Neurath M, Strober W . Interleukin-12 production by dendritic cells. The role of CD40-CD40L interactions in Th1 T-cell responses. Ann N Y Acad Sci. 1996; 795:116-26. DOI: 10.1111/j.1749-6632.1996.tb52660.x. View

15.

Ladoire S, Enot D, Andre F, Zitvogel L, Kroemer G . Immunogenic cell death-related biomarkers: Impact on the survival of breast cancer patients after adjuvant chemotherapy. Oncoimmunology. 2016; 5(2):e1082706. PMC: 4801435. DOI: 10.1080/2162402X.2015.1082706. View

16.

Lipsitz S, Kim K, Zhao L . Analysis of repeated categorical data using generalized estimating equations. Stat Med. 1994; 13(11):1149-63. DOI: 10.1002/sim.4780131106. View

17.

Mailliard R, Wankowicz-Kalinska A, Cai Q, Wesa A, Hilkens C, Kapsenberg M . alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res. 2004; 64(17):5934-7. DOI: 10.1158/0008-5472.CAN-04-1261. View

18.

Kiener P, Rankin B, Wahl A, Aruffo A, Hollenbaugh D . Stimulation of CD40 with purified soluble gp39 induces proinflammatory responses in human monocytes. J Immunol. 1995; 155(10):4917-25. View

19.

Van Gool S, Vandenberghe P, de Boer M, Ceuppens J . CD80, CD86 and CD40 provide accessory signals in a multiple-step T-cell activation model. Immunol Rev. 1996; 153:47-83. DOI: 10.1111/j.1600-065x.1996.tb00920.x. View

20.

Kepp O, Senovilla L, Vitale I, Vacchelli E, Adjemian S, Agostinis P . Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology. 2015; 3(9):e955691. PMC: 4292729. DOI: 10.4161/21624011.2014.955691. View